Drug Trial Radar · NCT07600151
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Sep 30, 2036
Study completion Dec 31, 2036
Sponsor
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbbVie; Sanofi
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.
Conditions
- Myeloma Multiple
- Myeloma
Interventions
EtentamigDrug
Administered per the protocol
IsatuximabDrug
Administered per the protocol
Bortezomib + Lenalidomide + DexamethasoneDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability (Phase I)Time frame: through induction treatment, on average 4 months
- MRD negativity (Phase II)Time frame: through consolidation phase completion, an average of 1 year
- PFSTime frame: up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.